Chimeric Therapeutics


Market CapAU$70m

Last Close AU$0.32

Chimeric Therapeutics, which is based in Australia and focused on oncology, recently went public on the ASX. Lead programme CLTX-CAR T is in Phase I for the treatment of GBM. This is an innovative approach for an unmet medical need. Beyond GBM, the technology may have applicability for other tumours such as melanoma.

More Chimeric Therapeutics content >

Investment summary

Chimeric Therapeutics is an Australia-based biotechnology company with a focus on oncology that has recently gone public on the ASX. In September 2020, Chimeric announced that it in-licensed CLTX CAR T, currently in Phase I. The study dosed its first patient in September 2020 (five patients in total have been dosed so far) and expects to enrol approximately 18–36 patients with recurrent/progressive glioblastoma (GBM). Chimeric also recently announced that it is licensing a CDH17 CAR T which may have broad applicability in solid tumours. Importantly, preclinical evidence suggests the therapy may be able to eradicate tumours with little to no toxicity to normal tissues. It is expected to enter the clinic in 2022.

Y/E Jun
Revenue (A$m)
PBT (A$m)
EPS (c)
P/E (x)
P/CF (x)
2019A N/A N/A N/A N/A N/A N/A
2020A 0.0 (0.1) (0.1) (6200.80) N/A N/A
2021E 0.0 (12.0) (12.0) (3.59) N/A N/A
2022E 0.0 (14.0) (14.0) (4.13) N/A N/A
Industry outlook

GBM (US incidence of around 12,000 per year) accounts for 60% of brain tumours in adults and continues to have a poor prognosis with five-year survival of only 5.1%. Total incidence for the cancers targeted by the CDH17 programme is estimated to be 248,490 in the United States.

Last updated on 21/09/2021
Content on Chimeric Therapeutics
Chimeric Therapeutics – Scorpion venom CAR-T stalking GBM
Healthcare | Initiation | 19 January 2021
Healthcare Sector reports: T-cell therapies Part 1-17092017-Feature image
View more
Register to receive research on Chimeric Therapeutics as it is published
Share price graph
Balance sheet
Forecast net cash (A$m) 22.4
Forecast gearing ratio (%) N/A
Price performance
Actual (3.0) 6.7 N/A
Relative* (1.0) 5.6 N/A
52-week high/low A$0.4/A$0.2
*% relative to local index
Key management
Paul Hopper Executive Chairman